<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30684">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707263</url>
  </required_header>
  <id_info>
    <org_study_id>15-01051</org_study_id>
    <nct_id>NCT02707263</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients</brief_title>
  <official_title>Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to demonstrate that a continuous infusion of
      intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore
      prophylactic levels of heparin in high-risk critically ill medical patients as compared with
      guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to
      measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood,
      will be used to demonstrate that Intravenous administration is more effective.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Coagulation (Anti-Xa levels) in patients receiving Intravenous Continuous Infusion Heparin versus subcutaneous Heparin</measure>
    <time_frame>3 Days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Intravenous continuous infusion of heparin (IV UFH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin will be administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin will be subcutaneously administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous continuous infusion of heparin (IV UFH)</intervention_name>
    <arm_group_label>Intravenous continuous infusion of heparin (IV UFH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Heparin</intervention_name>
    <arm_group_label>Subcutaneous heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to the medical ICU (MICU)

          -  High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:

          -  Body Mass Index (BMI) ≥ 30 kg/m2

          -  Personal or family history of VTE

          -  Receiving vasopressors

        Exclusion Criteria:

          -  Indication for therapeutic anticoagulation

          -  Evidence of deep vein thrombosis (DVT) on ultrasonography at admission

          -  Indwelling intrathecal, epidural, or other indwelling deep catheters

          -  Recent (&lt; 3 months) International Society of Thrombosis and Haemostasis (ISTH) major
             bleeding13

          -  Recent (&lt; 3 months) major trauma

          -  Recent (&lt; 3 months) neurosurgery or orthopedic surgery Pregnancy

          -  Contraindication to heparin or heparin products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Papadopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tyler Lewis</last_name>
    <email>lewist07@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Schwartz</last_name>
    <email>schwad01@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler Lewis</last_name>
      <email>lewist07@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>David Schwartz</last_name>
      <email>schwad01@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Papadopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 6, 2016</lastchanged_date>
  <firstreceived_date>March 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
